Article
Oncology
Yuki Zaizen, Masahito Nakano, Kazuta Fukumori, Yoichi Yano, Kota Takaki, Takashi Niizeki, Kotaro Kuwaki, Masaru Fukahori, Takahiko Sakaue, Sohei Yoshimura, Mika Nakazaki, Ryoko Kuromatsu, Shusuke Okamura, Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Hironori Koga, Takuji Torimura
Summary: Clinical studies have shown that immunotherapy is more effective than sorafenib for advanced hepatocellular carcinoma, but the outcomes of HAIC with cisplatin compared to sorafenib remain unclear. This study found that HAIC with cisplatin significantly prolonged overall survival for intrahepatic advanced HCC, particularly for patients in Child-Pugh class A.
Article
Gastroenterology & Hepatology
Min Kyung Park, Yun Bin Lee, Hyemi Moon, Na Ryung Choi, Minseok Albert Kim, Heejoon Jang, Joon Yeul Nam, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon
Summary: The effectiveness of lenvatinib and sorafenib is comparable in the treatment of unresectable hepatocellular carcinoma (HCC) in decompensated patients.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Review
Gastroenterology & Hepatology
Yin Long, Xingdong Song, Yan Guan, Ran Lan, Ziqi Huang, Senlin Li, Lei Zhang
Summary: This systematic review found that the combination of sorafenib and hepatic arterial infusion chemotherapy (HAIC) improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) compared with sorafenib alone in advanced hepatocellular carcinoma (HCC), with an acceptable safety profile.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Oncology
Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
Summary: For locally advanced HCC after LD-CCRT, the clinical efficacies of sequential treatment with HAIC and sorafenib were comparable in terms of overall survival, progression-free survival, and treatment response rates. Both treatment options showed similar results in terms of radiological objective response rate and conversion rate to surgical resection or liver transplantation. However, the HAIC group had worse profiles in terms of leukopenia and hypoalbuminemia as compared to the Sorafenib group in terms of treatment-related adverse events.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Run-Bin Liang, Yang Zhao, Min-Ke He, Dong-Sheng Wen, Xiao-Yun Bu, Ye-Xing Huang, Zhi-Cheng Lai, Yu-Jie Xu, Anna Kan, Wei Wei, Yao-Jun Zhang, Min-Shan Chen, Rong-Ping Guo, Qi-Jiong Li, Ming Shi
Summary: The study demonstrated that in patients with advanced hepatocellular carcinoma, using HAIC plus sorafenib may improve overall survival and progression free survival compared to HAIC alone. Additionally, the combination therapy showed a higher disease control rate in the patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Meiyue Li, Shen Lin, Leslie Wilson, Pinfang Huang, Hang Wang, Shubin Lai, Liangliang Dong, Xiongwei Xu, Xiuhua Weng
Summary: The study evaluated the cost-effectiveness of HAIC plus sorafenib (SoraHAIC) versus standard care for HCC patients from the Chinese health system perspective. The results indicated that SoraHAIC was not cost-effective in medium- and low-income regions of China, but there was a 38.8% probability that it would be cost-effective in developed areas (such as Beijing).
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Jaejun Lee, Ji-Won Han, Pil-Soo Sung, Soon-Kyu Lee, Hyun Yang, Hee-Chul Nam, Sun-Hong Yoo, Hae-Lim Lee, Hee-Yeon Kim, Sung-Won Lee, Jung-Hyun Kwon, Jeong-Won Jang, Chang-Wook Kim, Soon-Woo Nam, Jung-Suk Oh, Ho-Jong Chun, Si-Hyun Bae, Jong-Young Choi, Seung-Kew Yoon
Summary: The study revealed that in unresectable hepatocellular carcinoma patients, lenvatinib and hepatic artery infusion chemotherapy showed similar objective response rates and overall survival. However, for patients with a high tumor burden, hepatic artery infusion chemotherapy resulted in longer overall survival.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Hideki Iwamoto, Takashi Niizeki, Hiroaki Nagamatsu, Kazuomi Ueshima, Joji Tani, Teiji Kuzuya, Kazuhiro Kasai, Youhei Kooka, Atsushi Hiraoka, Rie Sugimoto, Takehiro Yonezawa, Satoshi Tanaka, Akihiro Deguchi, Shigeo Shimose, Tomotake Shirono, Miwa Sakai, Hiroyuki Suzuki, Etsuko Moriyama, Hironori Koga, Takuji Torimura, Takumi Kawaguchi
Summary: New-FP regimen of hepatic arterial infusion chemotherapy is effective for HCC patients with major portal vein tumor thrombus, showing improved survival compared to sorafenib in various tumor conditions.
Article
Oncology
Leye Yan, Junqing Lin, Kun Ke, Zhengzhong Wu, Jingyao Huang, Ning Huang, Weizhu Yang
Summary: Hepatic arterial infusion chemotherapy showed superior efficacy and safety compared to sorafenib for advanced hepatocellular carcinoma (HCC), making it a recommended treatment option for suitable patients.
TRANSLATIONAL CANCER RESEARCH
(2022)
Review
Chemistry, Multidisciplinary
Takahiro Yamasaki, Issei Saeki, Yurika Kotoh-Yamauchi, Ryo Sasaki, Norikazu Tanabe, Takashi Oono, Takashi Matsuda, Takuro Hisanaga, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Yutaka Suehiro, Isao Sakaida
Summary: The study discussed the clinical benefits of hepatic arterial infusion chemotherapy (HAIC) compared to sorafenib in treating patients with hepatocellular carcinoma (HCC), including the ability to treat a wider range of patients, minimal impact on Child-Pugh scores, and higher efficacy in patients with vascular invasion.
APPLIED SCIENCES-BASEL
(2021)
Review
Oncology
Wei Zhang, Deliang Ouyang, Zhangkan Huang, Xu Che
Summary: This study compared the efficacy of hepatic artery infusion chemotherapy (HAIC) versus sorafenib in patients with hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombus (PVTT). The results showed that HAIC group had significantly higher rates of complete response, partial response, objective response rate, and disease control rate compared to the sorafenib group. Moreover, the overall survival and progression-free survival rates were significantly higher in the HAIC group.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Mei Li, Kai Zhang, Ji'an He, Weihao Zhang, Tianye Lv, Li Wang, Wenge Xing, Haipeng Yu
Summary: In recent years, hepatic arterial infusion chemotherapy (HAIC) has gained popularity in the treatment of hepatocellular carcinoma. This bibliometric analysis examines the cooperation and influence among countries, institutions, authors, and journals in the field of HAIC. The results show that the use of HAIC in HCC treatment is on the rise, particularly in combination with targeted therapy or immunotherapy.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Masatsugu Ishii, Osamu Itano, Hideki Iwamoto, Taizo Hibi, Satoshi Itano
Summary: This study aimed to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) using 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class B. The results showed that this therapy was effective and safe for CP class B patients, and improvements in CP scores after 4 weeks of treatment may serve as a predictive marker of treatment efficacy.
Article
Health Care Sciences & Services
Amol Gupta, Jane Zorzi, Won Jin Ho, Marina Baretti, Nilofer Saba Azad, Paige Griffith, Doan Dao, Amy Kim, Benjamin Philosophe, Christos Georgiades, Ihab Kamel, Richard Burkhart, Robert Liddell, Kelvin Hong, Christopher Shubert, Kelly Lafaro, Jeffrey Meyer, Robert Anders, William Burns III, Mark Yarchoan
Summary: This study examined the relationship between health-related quality of life (HRQoL) and Barcelona Clinic Liver Cancer (BCLC) stage, Child-Pugh (CP) score, and Eastern Cooperative Oncology Group (ECOG) performance status in patients with hepatocellular carcinoma (HCC). The results showed that impaired liver function was associated with reduced quality of life, while the BCLC stage had poor correlation with HRQoL. Early supportive interventions may have a positive impact on HRQoL and survival outcomes for HCC patients.
Article
Oncology
Hideki Iwamoto, Takashi Niizeki, Hiroaki Nagamatsu, Kazuomi Ueshima, Takako Nomura, Teiji Kuzuya, Kazuhiro Kasai, Yohei Kooka, Atsushi Hiraoka, Rie Sugimoto, Takehiro Yonezawa, Akio Ishihara, Akihiro Deguchi, Hirotaka Arai, Shigeo Shimose, Tomotake Shirono, Masahito Nakano, Shusuke Okamura, Yu Noda, Naoki Kamachi, Miwa Sakai, Hiroyuki Suzuki, Hajime Aino, Norito Matsukuma, Satoru Matsugaki, Kei Ogata, Yoichi Yano, Takato Ueno, Masahiko Kajiwara, Satoshi Itano, Kunitaka Fukuizumi, Hiroshi Kawano, Kazunori Noguchi, Masatoshi Tanaka, Taizo Yamaguchi, Ryoko Kuromatsu, Atsushi Kawaguchi, Hironori Koga, Takuji Torimura
Summary: The study found that local treatment with New-FP is potentially superior to systemic treatment with sorafenib as an initial treatment for locally progressed HCC without extrahepatic spread.
Article
Multidisciplinary Sciences
Tomoki Nishikawa, Naoto Nagata, Tetsuro Shimakami, Takashi Shirakura, Chieko Matsui, Yinhua Ni, Fen Zhuge, Liang Xu, Guanliang Chen, Mayumi Nagashimada, Taro Yamashita, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Masao Honda, Shuichi Kaneko, Tsuguhito Ota
SCIENTIFIC REPORTS
(2020)
Article
Endocrinology & Metabolism
Yumie Takeshita, Takehiro Kanamori, Takeo Tanaka, Yuka Kaikoi, Yuki Kita, Noboru Takata, Noriho Iida, Kuniaki Arai, Tatsuya Yamashita, Kenichi Harada, Toshifumi Gabata, Hiroyuki Nakamura, Shuichi Kaneko, Toshinari Takamura
Article
Gastroenterology & Hepatology
Takeshi Terashima, Tatsuya Yamashita, Noboru Takata, Tadashi Toyama, Tetsuro Shimakami, Hajime Takatori, Kuniaki Arai, Kazunori Kawaguchi, Kazuya Kitamura, Taro Yamashita, Yoshio Sakai, Eishiro Mizukoshi, Masao Honda, Shuichi Kaneko
HEPATOLOGY RESEARCH
(2020)
Article
Gastroenterology & Hepatology
Takeshi Terashima, Masao Honda, Tadashi Toyama, Tetsuro Shimakami, Ryogo Shimizu, Hajime Takatori, Kuniaki Arai, Kazunori Kawaguchi, Kazuya Kitamura, Taro Yamashita, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Shuichi Kaneko
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2020)
Article
Gastroenterology & Hepatology
Takeshi Terashima, Tatsuya Yamashita, Noboru Takata, Yasuhito Takeda, Hidenori Kido, Noriho Iida, Masaaki Kitahara, Tetsuro Shimakami, Hajime Takatori, Kuniaki Arai, Kazunori Kawaguchi, Kazuya Kitamura, Taro Yamashita, Yoshio Sakai, Eishiro Mizukoshi, Masao Honda, Shuichi Kaneko
Summary: Sequential administration of sorafenib followed by regorafenib or lenvatinib is effective against advanced hepatocellular carcinoma, with similar safety profiles observed between sorafenib and regorafenib but differences in adverse events and anti-tumor effects between sorafenib and lenvatinib. The results provide insights for selecting sequential therapy for patients with advanced HCC.
HEPATOLOGY RESEARCH
(2021)
Article
Multidisciplinary Sciences
Shinichi Hashimoto, Takayoshi Shirasaki, Taro Yamashita, Sadahiro Iwabuchi, Yutaka Suzuki, Yuzuru Takamura, Yoshiaki Ukita, Shungo Deshimaru, Toshitugu Okayama, Kazuho Ikeo, Kazuyuki Kuroki, Kazunori Kawaguchi, Eishiro Mizukoshi, Kouji Matsushima, Masao Honda, Shuichi Kaneko
Summary: Using single-cell RNA sequencing analysis, four genes including DOCK11 and DENND2A were identified to be linked to the maintenance of HBV in liver cells. Knockdown of these genes in primary human hepatocytes infected with HBV resulted in a decrease in both HBV DNA and covalently closed circular DNA. This study reveals a role for DOCK11 and DENND2A in maintaining HBV in a latent state.
Article
Biochemistry & Molecular Biology
Tsuyoshi Suda, Taro Yamashita, Hajime Sunagozaka, Hikari Okada, Kouki Nio, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Masao Honda, Shuichi Kaneko
Summary: This study evaluated the potential of serum DKK-1 as a diagnostic and prognostic marker for hepatocellular carcinoma (HCC). The results showed that DKK-1 levels were significantly elevated in HCC patients and high levels were associated with poor prognosis. The study also demonstrated that anti-DKK-1 antibody treatment inhibited tumor growth, while recombinant DKK-1 promoted cell proliferation, invasion, and angiogenesis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Multidisciplinary Sciences
Eishiro Mizukoshi, Hidetoshi Nakagawa, Toshikatsu Tamai, Masaaki Kitahara, Kazumi Fushimi, Kouki Nio, Takeshi Terashima, Noriho Iida, Kuniaki Arai, Tatsuya Yamashita, Taro Yamashita, Yoshio Sakai, Masao Honda, Shuichi Kaneko
Summary: This study found that peptide-specific T cell responses can persist for more than 10 years following vaccination in hepatocellular carcinoma patients. Tumor-specific memory CD8 T cells are able to persist and possibly even proliferate in the peripheral blood of long-surviving patients.
NATURE COMMUNICATIONS
(2022)
Article
Biochemistry & Molecular Biology
Ru Li, Hikari Okada, Taro Yamashita, Kouki Nio, Han Chen, Yingyi Li, Tetsuro Shimakami, Hajime Takatori, Kuniaki Arai, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Masao Honda, Shuichi Kaneko
Summary: This study demonstrates that the transcription factor FOXM1 plays a pivotal role in the proliferation of AFP-positive liver cancer cells. The upregulation of FOXM1 is associated with high serum AFP levels, microscopic portal vein invasion, and poor prognosis in HCC patients. Furthermore, the inhibition of FOXM1 expression using the proteasome inhibitor carfilzomib reduces AFP expression and suppresses cell proliferation in AFP-positive HCC cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Shihui Li, Eishiro Mizukoshi, Kazunori Kawaguchi, Miyabi Miura, Michiko Nishino, Tetsuro Shimakami, Kuniaki Arai, Taro Yamashita, Yoshio Sakai, Tatsuya Yamashita, Masao Honda, Shuichi Kaneko
Summary: This study investigated the immune responses to hepatocellular carcinoma (HCC) influenced by direct-acting antivirals (DAAs) in patients with hepatitis C virus (HCV) infection and elucidated the underlying mechanisms. The results showed that DAAs can enhance immune responses to HCC by reducing the frequency of specific immune cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Takeshi Terashima, Tatsuya Yamashita, Naoki Takemura, Anri Inaki, Akinori Shimizu, Kenichi Harada, Taro Yamashita, Seigo Kinuya, Keiji Hanada
Summary: A 59-year-old woman with metastatic pancreatic insulinoma experienced frequent hypoglycemic attacks that were refractory to conventional therapy. However, treatment with CAPTEM and PRRT resulted in a significant decrease in the frequency of hypoglycemic attacks and shrinkage of the tumor.
CLINICAL JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Biochemistry & Molecular Biology
Tsuyoshi Suda, Hajime Takatori, Takehiro Hayashi, Kiichiro Kaji, Kouki Nio, Takeshi Terashima, Tetsuro Shimakami, Kuniaki Arai, Tatsuya Yamashita, Eishiro Mizukoshi, Masao Honda, Kenichiro Okumura, Kazuto Kozaka, Taro Yamashita
Summary: Liver function affects plasma antithrombin (AT)-III levels, which are beneficial for patients with portal vein thrombosis (PVT) and low AT-III levels. However, the impact of these levels on prognosis in cirrhosis-associated PVT patients is unknown. A retrospective study of 75 cirrhosis and PVT patients treated with danaparoid sodium with or without AT-III found that low plasma AT-III levels were associated with worse prognosis, particularly liver failure-related death, independent of liver function.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Noriho Iida, Eishiro Mizukoshi, Tatsuya Yamashita, Masahiro Yutani, Jun Seishima, Ziyu Wang, Kuniaki Arai, Hikari Okada, Taro Yamashita, Yoshio Sakai, Yusuke Masuo, Rina Agustina, Yukio Kato, Yukako Fujinaga, Masanobu Oshima, Masao Honda, Francois Lebreton, Michael S. Gilmore, Shuichi Kaneko
Summary: The study revealed that Enterococcus faecalis is abundant in the microbiota of patients with hepatitis C virus-related chronic liver disease, promoting liver carcinogenesis via the TLR4-Myd88 signaling pathway.